My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 105

    1.

    Gait dynamics in mouse models of Parkinson's disease and Huntington's disease.

    Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG.

    J Neuroeng Rehabil. 2005 Jul 25;2:20.PMID: 16042805 [PubMed]Related articlesFree article

    2.

    Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis.

    Guillot TS, Asress SA, Richardson JR, Glass JD, Miller GW.

    J Mot Behav. 2008 Nov;40(6):568-77.PMID: 18980909 [PubMed - indexed for MEDLINE]Related articles

    3.

    A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty.

    Kurz MJ, Pothakos K, Jamaluddin S, Scott-Pandorf M, Arellano C, Lau YS.

    Neurosci Lett. 2007 Dec 11;429(1):39-42. Epub 2007 Oct 5.PMID: 17977658 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.

    Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL.

    Mov Disord. 1998 May;13(3):428-37. Erratum in: Mov Disord 1998 Jul;13(4):757. PMID: 9613733 [PubMed - indexed for MEDLINE]Related articles

    5.

    Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis.

    Hausdorff JM, Lertratanakul A, Cudkowicz ME, Peterson AL, Kaliton D, Goldberger AL.

    J Appl Physiol. 2000 Jun;88(6):2045-53.PMID: 10846017 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Ethanol's effects on gait dynamics in mice investigated by ventral plane videography.

    Kale A, Amende I, Meyer GP, Crabbe JC, Hampton TG.

    Alcohol Clin Exp Res. 2004 Dec;28(12):1839-48.PMID: 15608600 [PubMed - indexed for MEDLINE]Related articles

    8.

    Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study.

    Delval A, Krystkowiak P, Blatt JL, Labyt E, Dujardin K, Destée A, Derambure P, Defebvre L.

    J Neurol. 2006 Jan;253(1):73-80. Epub 2005 Aug 17.PMID: 16096818 [PubMed - indexed for MEDLINE]Related articles

    9.

    Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.

    Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F.

    Eur J Neurosci. 2004 Jun;19(12):3266-76.PMID: 15217383 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently.

    Frenkel-Toledo S, Giladi N, Peretz C, Herman T, Gruendlinger L, Hausdorff JM.

    J Neuroeng Rehabil. 2005 Jul 31;2:23.PMID: 16053531 [PubMed]Related articlesFree article

    13.

    Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome.

    Hampton TG, Stasko MR, Kale A, Amende I, Costa AC.

    Physiol Behav. 2004 Sep 15;82(2-3):381-9.PMID: 15276802 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

    Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vucković M, Fisher BE, Togasaki DM, Jakowec MW.

    J Neurosci. 2007 May 16;27(20):5291-300.PMID: 17507552 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.

    Byler SL, Boehm GW, Karp JD, Kohman RA, Tarr AJ, Schallert T, Barth TM.

    Behav Brain Res. 2009 Mar 17;198(2):434-9. Epub 2008 Nov 25.PMID: 19070633 [PubMed - indexed for MEDLINE]Related articles

    16.

    Coenzyme Q10 as a possible treatment for neurodegenerative diseases.

    Beal MF.

    Free Radic Res. 2002 Apr;36(4):455-60. Review.PMID: 12069110 [PubMed - indexed for MEDLINE]Related articles

    17.

    Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.

    Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, Greene JG.

    Exp Neurol. 2007 Sep;207(1):4-12. Epub 2007 May 18.PMID: 17586496 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

    Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF.

    J Neurochem. 2009 Jun;109(5):1427-39. Epub 2009 Mar 28.PMID: 19476553 [PubMed - indexed for MEDLINE]Related articles

    19.

    Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

    Pattarini R, Smeyne RJ, Morgan JI.

    Neuroscience. 2007 Mar 16;145(2):654-68. Epub 2007 Jan 29.PMID: 17258864 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.

    Shin JY, Park HJ, Ahn YH, Lee PH.

    J Neurochem. 2009 Nov;111(4):1042-50. Epub 2009 Sep 16.PMID: 19765187 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Write to the Help Desk